Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice

Mary Lynn Zaremba, Kristin Elliott, Alicia Redford, Syed Ali, Nipurn Shah, Sridhar Reddy
European Respiratory Journal 2011 38: p4000; DOI:
Mary Lynn Zaremba
St. Clair Pulmonary & Critical Care, 1210 10th Avenue, Port Huron, MI, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristin Elliott
St. Clair Pulmonary & Critical Care, 1210 10th Avenue, Port Huron, MI, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia Redford
St. Clair Pulmonary & Critical Care, 1210 10th Avenue, Port Huron, MI, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syed Ali
St. Clair Pulmonary & Critical Care, 1210 10th Avenue, Port Huron, MI, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nipurn Shah
St. Clair Pulmonary & Critical Care, 1210 10th Avenue, Port Huron, MI, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sridhar Reddy
St. Clair Pulmonary & Critical Care, 1210 10th Avenue, Port Huron, MI, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

In 1961, Orie and colleagues from the University of Groningen in the Netherlands hypothesized that the various forms of airway obstruction, such as asthma, chronic bronchitis and emphysema, should be considered not as separate entities but as different expressions of one disease entity. In a pulmonary practice patients with a physician diagnosis of chronic obstructive pulmonary disease (COPD) had physiological and biochemical evaluation as part of their routine workup. They were treated with omalizumab if they were symptomatic despite adequate conventional treatment and had an elevated IgE level. Patients with COPD (n=60) who were on treatment with omalizumab for at least 6 months were asked to fill out a questionnaire from which their symptom scores (1-4) and satisfaction scores (1-5) were extracted. There was statistically significant improvement in the amelioration of both symptoms and increase in satisfaction scores (p was less than 0.01) with treatment with omalizumab. This year being the 50th anniversary of the Dutch Hypothesis, it may be appropriate to revisit this issue. Patients with COPD may benefit from evaluation and treatment with monoclonal anti-IgE antibody therapy. Randomized placebo controlled, double blinded trials are needed to help further define the role of anti IgE therapy in patients with COPD. Subsequently, the broad use of biomarkers to evaluate need for monoclonal antibody therapy may need to be reconsidered. To the treating physician and the patient the treatment outcome is more relevant than the actual diagnosis.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice
Mary Lynn Zaremba, Kristin Elliott, Alicia Redford, Syed Ali, Nipurn Shah, Sridhar Reddy
European Respiratory Journal Sep 2011, 38 (Suppl 55) p4000;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice
Mary Lynn Zaremba, Kristin Elliott, Alicia Redford, Syed Ali, Nipurn Shah, Sridhar Reddy
European Respiratory Journal Sep 2011, 38 (Suppl 55) p4000;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease
  • A comparative study to evaluate the effects of salmetrol/fluticasone and formoterol/budesonide combinations on lung functions and sleep quality in asthma
Show more 415. Airways disease comorbidities and general aspects

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society